We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
- Authors
Held, Lauren A; Rizzieri, David; Long, Gwynn D; Gockerman, Jon P; Diehl, Louis F; de Castro, Carlos M; Moore, Joseph O; Horwitz, Mitchell E; Chao, Nelson J; Gasparetto, Cristina
- Abstract
This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcade™) (AAV) for patients with relapsed/refractory multiple myeloma.
- Publication
Cancer investigation, 2013, Vol 31, Issue 3, p172
- ISSN
1532-4192
- Publication type
Journal Article
- DOI
10.3109/07357907.2012.756109